Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery!
Quiz|Articles|September 20, 2026 (Updated: September 17, 2026)
NeurologyLive® Brain Games: September 20, 2026
Author(s)Louie Pasculli, Marco Meglio
Listen
0:00 / 0:00
Key Takeaways
- A Sunday-release cadence structures a three-question format intended to assess breadth across major neurology subspecialties.
- Clinician- and expert-written questions integrate both clinical practice and historical context within neurological disease domains.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease biomarkers!
Advertisement
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.
This week's questions includes the theme of Parkinson disease biomarkers!
Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email:
A 67-year-old patient has bradykinesia, rigidity, and a resting tremor, but the clinical diagnosis remains uncertain. Cerebrospinal fluid testing demonstrates a positive α-synuclein seed amplification assay (αSyn-SAA). Which interpretation is most appropriate?
A neurologist is evaluating a patient with suspected Parkinson disease and is considering dopamine transporter (DAT) SPECT imaging. Which finding would most strongly support a presynaptic dopaminergic deficit?
A patient with early Parkinson disease has a positive CSF αSyn-SAA. Investigators subsequently observe that the assay remains positive over serial assessments despite clinical progression. Which statement best describes the current limitation of αSyn-SAA as a longitudinal biomarker?
How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!
How many questions did you get correct?
Advertisement
Related to this article
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]
Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.
At a NeurologyLive Clinical Forum in Phoenix, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how a lack of adult neuro-oncology infrastructure is shaping how NF1-associated plexiform neurofibromas get recognized, referred, and treated.
The FDA granted fast track designation to FRP-003, an investigational oral botanical drug candidate for Long COVID, ahead of a planned phase 2 trial evaluating fatigue in approximately 220 adults.
GV101 receives FDA fast track designation for the treatment of Friedreich ataxia, with a phase 2 trial planned to begin enrollment in late 2026.
In honor of Veterans Day, Clayton Mucha, DO, neurorehabilitation physiatrist at Burke Rehabilitation in New York, discusses the lasting effects of traumatic brain injury in military personnel.
At a NeurologyLive Clinical Forum in New York, Mary Ann Piccone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
2
FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study
3
Headlining Current Advances and Challenges in Multiple Sclerosis Care
4
Optimizing and Personalizing Treatment in Generalized Myasthenia Gravis
5